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Abstract
Background: The feasibility and clinical implication of drug monitoring of morphine, morphine-6-glucuronide (M6G)
and morphine-3-glucuronide (M3G) need further investigation. This study aimed to determine what predicts serum
concentrations of morphine in cancer patients receiving continuously intravenous morphine, the relationships between
serum concentration of morphine/its metabolites and urinary concentrations, and the relation between morphine
concentrations and with clinical outcomes.
Methods: We collected serum and urine samples from 24 patients with advanced cancer undergoing continuously
intravenous morphine therapy. Serum samples were obtained at day one. Spot urine samples were collected once daily
on three consecutive days. Pain and adverse drug events were assessed using the Korean version of MD Anderson
Symptom Inventory.
Results: A total of 96 samples (72 urine and 24 serum samples) were collected. Median dose of morphine was
82.0 mg/24 h. In a multivariate analysis, total daily morphine dose was the most significant predictors of both
serum and urine concentration of morphine. Morphine, M6G, and M3G in serum and urine were statistical significantly
correlated (correlation coefficient = 0.81, 0.44, 0.56; p values < 0.01, 0.03, 0.01, respectively).
Conclusion: Spot urine concentrations of morphine and its metabolites were highly correlated to those of serum. Total
dose of daily morphine was related to both serum and urine concentration of morphine and its metabolites.
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Background
Morphine is the most used treatment for moderate or
severe pain in advanced cancer patients. However, there
has been stigma related to morphine among patients
and their families. Many patients receiving morphine en-
counter adverse events of morphine such as drowsiness
and nausea, and in extreme cases morphine leads to
opioid-induced neurotoxicity (OIN) [1]. One distinctive
feature of morphine responsiveness is that there are high
inter-individual variations in the needed dose among
patients [2]. Previous studies suggest that variable bio-
availability, metabolism and elimination of morphine
and its metabolites might explain some of the variability
in doses [3]. Morphine is metabolized into morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G).
M6G has been suggested to have higher analgesic potency
than morphine, and may cause nausea and sedation [4].
M3G has been reported to exert an antianalgesic effect,
and is suggested to elicit neurotoxicity [5]. However, the
relation between morphine metabolites and clinical
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symptoms is still controversial [6–8]. In previous studies,
most patients use oral morphine, and most studies are
performed in one ethnic group, Caucasians. Therefore, a
study including non-Caucasian patients would be of inter-
est. Thus, this study aimed to investigate in Korean inpa-
tients with advanced cancer receiving continuously
intravenous morphine; 1) What predicts serum and urine
concentration of morphine and its metabolites, and 2)




This was a prospective observational study for inpa-
tients with advanced cancer of a university hospital in
South Korea. The institutional review board (IRB) of
the study hospital approved this study (IRB Number:
KC12TIS10076). All patients participated in this study
provided written informed consents.
Study participants
Twenty-four Korean patients with far advanced cancer
who were admitted to Seoul St. Mary’s hospital from July
2012 till October 2013 were enrolled in this study.
Patients who were more than 18 years old receiving con-
tinuous intravenous morphine treatment for more than
three days were included. To minimize variability due to
gastrointestinal absorption and first-pass metabolism, we
only included patients receiving intravenous morphine.
We excluded patients who were unable to answer to
questions regarding pain, adverse events and health
status. Patients who had alterations in consciousness
caused by organic brain diseases such as dementia,
stroke or, brain metastasis were excluded. Patients with
anuria (urine output <100 ml/day), bowel obstruction
(based on clinical and radiologic findings), liver dysfunc-
tion (alanine transaminase ≥100 IU/l) and renal dysfunc-
tion (serum creatinine ≥ 2.0 mg/dl) were also excluded.
Assessments of clinical variables
At inclusion age, gender, and cancer type were registered.
Patients’ functional status was assessed using Karfnosky
performance status. Alanine aminotransferase and creatin-
ine measurements were determined using standard analyt-
ical methods. The daily amount of intravenous fluid, daily
urine output, daily total dosage of morphine were regis-
tered for all three days of the study.
Pain, adverse events of morphine (drowsiness, nausea,
confusion) and health status were rated by the patients
using numeric rating scale (0 ~ 10). Items for drowsiness
and nausea were adopted from the symptom scales of
MD Anderson symptom inventory-Korean (MDASI-K).
The scales describe patient’s symptoms during the last
24 h, with 0 being “not at all” while 10 being “as bad as
you can imagine”. A research nurse explained confusion
as ‘decrement of concentration ability, difficulty in paying
attention’ during the interview. Health status was checked
using a self-rated item from 0 representing “worst imagin-
able health status” to 100 representing “best imaginable
health status”.
Samples and analyses of blood and urine
We obtained urinary samples besides blood samples in
order to observe if urine concentrations of morphine and
metabolites reflect serum concentrations. Blood samples
to measure serum concentrations of morphine and its me-
tabolites were drawn during the routine morning collec-
tion of blood tests. EDTA tubes were used, and serum was
separated by centrifugation and stored at −70 °C. We ob-
tained serum samples at day 1 and three consecutive urine
samples from day one to day three (D3) of the study.
Urine samples were gathered as the first spot urine in the
morning. Urine samples were put in tubes with no addi-
tives and stored at −70 °C. All samples were analyzed at
the Department of Laboratory Medicine, Bundang Seoul
National University (Gyeonggido, South Korea). Samples
were analyzed for concentrations of morphine, M6G and
M3G by using ultra performance liquid chromatography-
tandem mass spectrometry (Waters Aquity UPLC Xevo
TQ-S, Waters, Watford, United Kingdom). Its limits of
detection were: 2.5 ng/ml for morphine, 2.0 ng/ml for
M6G, and 2.0 ng/ml for M3G. The analytical coefficients
of variation were: 5.0–5.2 % for morphine, 6.4–6.9 % for
M6G, and 5.9–7.0 % for M3G.
Statistical analysis
Results were shown in medians and ranges. Correlations
of urine and serum concentrations was examined using
Spearman method. The relationships of morphine dose
and its serum and urine concentrations were evaluated
by linear regression analysis. Interpatient variations in
morphine concentrations were investigated by calculat-
ing the individual urine/serum ratios and creating box
plots for the ratios. The relationship between serum and
urine concentrations and clinical outcomes were ana-
lyzed with the Spearman correlation. Analyses were con-
ducted using IBM SPSS version 21 (Statistical Package
for Social Services, Chicago, IL). Statistical significance
was defined as a p-value < 0.05.
Results
Baseline characteristics of patients
The median age of patients was 62.5 years and 75 %
(18/24) were males (Table 1). The most frequent site
of cancer was colon/rectum, pancreas and stomach in
a descending order. Patients’ median Karnofsky per-
formance status was 60. The reason for admission
was mainly for pain control and supportive care with
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the exception of three patients who were admitted for
chemotherapy. All patients received morphine for at least
three days prior to study enrollment. The median of total
dose of intravenous morphine during the study period
was 82 mg/day (D1, D3) and 153.4 mg/day (D2). The me-
dian of administered intravenous fluid amount was 1050
~ 1210 ml/day while that of urine output was 1500 ml/
day. The patients self-reports of symptoms are given in
Table 1.
Serum and urine concentrations of morphine, M6G, M3G
and metabolic ratios
On D1, the median of morphine concentration was
268.8 nmol/liter in the serum and 33293.9 nmol/liter in
the urine (Table 2). On D1, the M6G concentration was
216.7 nmol/liter in the serum and 11485.3 nmol/liter in
the urine. The M3G concentration on D1 was
1036.6 nmol/liter in the serum and 34780.8 nmol/liter
in the urine. The ratio of M6G/M was 0.62 in the
serum and 0.82, 0.76, 0.64 in the urine on D1, D2, and
D3, respectively. The ratio of M3G/M was 3.12 in the
serum and in urine 1.70, 1.65, 1.97 on D1, D2, D3, re-
spectively (Table 2).
Correlation of serum and urine concentrations
All concentrations of morphine, M6G and M3G in the
serum were significantly correlated to its urine concen-
tration (Table 3).
Clinical characteristics and concentrations of morphine
and metabolites
Daily morphine dose was significantly correlated to con-
centrations of morphine and metabolites concentrations
in both serum and urine (Table 4) and multiple linear
regression showed that total daily morphine dose ex-
plained the majority of the variability of serum and urine
concentrations as noted from the low R-square values
when omitting morphine dose from the models (Table 5).
We observed no significant correlation between serum
or urine morphine or metabolite concentrations with
clinical outcomes (data not shown)
Table 1 Demographic and clinical characteristics of study





Age (years) 62.5 (38, 80)a
Karnofsky Performance Status 60 (50, 80)a
Cancer type
Stomach 4 (16.7)






Total intravenous morphine dose (mg/day)
Day 1 82 (14, 1000)a
Day 2 153.5 (2, 1120)a
Day 3 82.0 (0, 1132)a
Pain (NRS, 0 ~ 10)
Day 1 5.0 (0, 9)a
Day 2 5.0 (0, 7)a
Day 3 4.5 (0, 9)a
Drowsiness (NRS, 0 ~ 10)
Day 1 5.0 (0, 10)a
Day 2 5.0 (0, 10)a
Day 3 3.5 (0, 10)a
Confusion (NRS, 0 ~ 10)
Day 1 5.0 (0, 10)a
Day 2 3.0 (0, 10)a
Day 3 3.0 (0, 10)a
Nausea (NRS, 0 ~ 10)
Day 1 2.0 (0, 10)a
Day 2 0.0 (0, 10)a
Day 3 1.0 (0, 10)a
Health status (NRS, 0 ~ 10)
Day 1 5.0 (0, 10)a
Day 2 6.0 (0, 9)a
Day 3 5.5 (0, 9)a
Total intravenous fluid (ml/day)
Day 1 1106.5 (200, 2019)a
Day 2 1210.5 (0, 2088)a
Day 3 1050.0 (0, 2240)a
Total urine output (ml/day)
Day 1 1500.0 (490, 2900)a
Table 1 Demographic and clinical characteristics of study
participants (n = 24) (Continued)
Day 2 1500.0 (600, 3300)a
Day 3 1550.0 (250, 3450)a
Laboratory variables
Alanine transaminase (IU/L) 23 (6, 75)a
Creatinine (mg/dl) 0.7 (0.4, 1.7)a
a Value represents median (minimum, maximum)
NRS numeric rating scale
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Discussion
Our study revealed that spot urine concentrations of
morphine and its metabolites were highly correlated to
those in the serum, and that morphine dose was the im-
portant predictor of both serum and urine concentra-
tions of morphine.
This study was different from previous studies in terms
of subjects and the route of drug administration. Our sub-
jects were all inpatients undergoing morphine therapy
through the intravenous route. Intravenous route omits
variable gastric absorption, and it is not influenced by first
pass metabolism. In addition to this, all patients had
received a continuous intravenous infusion of morphine
for more than three days prior to study commencement
ensuring stable serum morphine concentrations. More-
over, we measured both concentrations of morphine/me-
tabolites in serum and urine samples.
To the best of our knowledge, this is the first study
that investigated the use of urine samples with serum
samples for in morphine drug monitoring in cancer pa-
tients. Our study findings highlight the usefulness of
urine test in patients undergoing intravenous morphine
therapy. The advantages of urine test are its technical
simplicity, painless collection and inexpensiveness [9, 10].
The urine samples in our study were only morning spot
urine and not collected throughout a 24-h period. In spite
of the simple method, our urine test results showed sig-
nificant relationships with the corresponding serum obser-
vations. Interestingly, one recent study compared opioid
concentrations of oral fluid with those of serum [11]. This
study reported that oral fluid was a valid substitute for
serum sampling for patients on chronic oral morphine
therapy. We believe that urine analysis is even more famil-
iar to the patients.
We confirmed that the total dose of daily morphine
was related to the both serum and urine concentration
of morphine, M6G and M3G. A similar relationship was
demonstrated by Klepstad et al. [12], while a recent
study showed a poor correlation between morphine dose
and serum concentrations [13]. There are at least two
factors that may explain such an inconsistency. First,
there is a well-known inter-individual variability in the
pharmacokinetics of morphine. The wide inter-
individual variability including outliers reduce correl-
ation between dose and serum, concentrations. Second,
is the different route of administration for morphine. In
our study, the correlation was strong and significant des-
pite of its small sample size probably because the
Table 2 Serum and urine concentrations of morphine, metabolites,




M (nmol/l) 268.8 5617.8 35.0–70302.6
M6G (nmol/l) 216.7 613.6 21.7–5229.1
M3G (nmol/l) 1036.6 2372.8 108.4–24160.2
M6G/M (nmol/l) 0.6 1.6 0.0–9.3
M3G/M (nmol/l) 3.1 5.0 0.1–21.5
Urine
Day1
M (nmol/l) 33293.9 253924.0 1051.4–1380117.6
M6G (nmol/l) 11485.3 31195.6 1267.3–268278.9
M3G (nmol/l) 34780.8 81053.0 3828.9–518352.5
M6G/M (nmol/l) 0.8 0.8 0.0–2.0
M3G/M (nmol/l) 1.7 1.9 0.1–5.6
Day2
M (nmol/l) 23130.5 407484.6 1401.8–3078804.8
M6G (nmol/l) 10726.8 72322.2 1733.6–1177133.4
M3G (nmol/l) 37272.8 227898.7 4664.5–4007047.2
M6G/M (nmol/l) 0.8 0.7 0.0–1.3
M3G/M (nmol/l) 1.7 1.7 0.1–4.0
Day3
M (nmol/l) 19625.9 122126.5 350.5–2695750.3
M6G (nmol/l) 12568.8 56816.3 650.1–686950.1
M3G (nmol/l) 32938.8 460521.7 2600.4–1372594.1
M6G/M (nmol/l) 0.6 0.9 0.0–4.7
M3G/M (nmol/l) 2.0 2.6 0.1–15.2
M Morphine, M6G Morphine-6-glucuronide, M3G Morphine-3-glucuronide
Table 3 The correlation coefficients of morphine/morphine metabolites/metabolic ratios between serum and urine (n = 24)
M (nmol/liter) M6G (nmol/liter) M3G (nmol/liter) M6G/M M3G/M
Coefficient (p-value) 0.81(<0.01) 0.44 (0.03) 0.56 (0.01) 0.82 (<0.01) 0.76 (<0.01)
M Morphine, M6G Morphine-6-glucuronide, M3G Morphine-3-glucuronide
P-values are derived from spearman rank correlation
Table 4 The correlation coefficients between total morphine dose
and morphine concentration, and its metabolites in serum and
urine (n= 24)
M M6G M3G
Serum (Day1) 0.53 (0.01) 0.58 (0.00) 0.72 (<0.01)
Urine (Day1) 0.44 (0.03) 0.68 (<0.01) 0.65 (<0.01)
Urine (Day2) 0.47 (0.02) 0.46 (0.02) 0.51 (0.01)
Urine (Day3) 0.55 (0.01) 0.76 (<0.01) 0.65 (<0.01)
M Morphine, M6G Morphine-6-glucuronide, M3G Morphine-3-glucuronide
P-values are parenthesized and derived from spearman rank correlation
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intravenous route eliminated variability due to intestinal
absorption or first pass effect.
According to a systematic review, the weighted
mean ratios in serum between morphine and metabo-
lites were 6 (range: 0.2–15) for M3G:M and 0.9
(range: 0.03–2.6) for M6G: M in patients with normal
renal function given intravenous morphine [14] com-
pared to ratios in serum of 3.1 for M3G: M and 0.6
for M6G: M in our study. However, the ratios in our
study is within the range reported by Faura et al. sug-
gesting that limited sample size in our and others
studies may explain some variability in numbers be-
tween studies. We observed that the urine ratios were
1.7–2.0 and 0.6–0.8 for M3G:M and M6G:M, respect-
ively. Urine ratios are not available in previous stud-
ies. Thus, we could not compare our data to others.
While monitoring of concentrations of morphine
and morphine metabolites is generally not believed to
be important for routine drug monitoring [6], it can
be useful for detecting accumulation of morphine and
morphine metabolites. High serum concentrations of
opioids is known to be associated with fatal opioid over-
doses [15, 16]. This is particularly relevant to patients with
renal dysfunction who are at higher risk of developing opi-
oid toxicities due to reduced clearance of active metabolites.
Some investigators have suggested that increased M3G
concentrations may cause neuroexitatory adverse effects
[5], have an anti-analgesic effect [17], or cause nausea in pa-
tients with renal failure [3]. Furthermore, dehydration, drug
interactions and infections may increase accumulation of
metabolites, especially in elderly patients [1]. Therefore,
drug monitoring using a non-invasive method during opi-
oid therapy might be valuable in examining unexpected
clinical effects. However, its use in clinical practice is cur-
rently unestablished and remains limited to research
purposes.
We recognize that this study has some limitations.
Firstly, because our patients were a small and
heterogenous group of advanced cancer patients, this
study may be unable reveal meaningful relationships be-
tween symptoms and drug/metabolites concentrations.
Secondly, serum concentrations of morphine metabolites
are known to be higher in patients with renal impair-
ment and thus these patients have a higher risk of nau-
sea, vomiting and confusion [3]. Because patients with
renal failure were excluded from our study, relationships
relevant for cancer patients with renal failure were not
detected in our analyses. Thirdly, one may raise a ques-
tion about the wide range of morphine dosages in our
study subjects. At the time of study enrollment, our pa-
tients had been receiving intravenous morphine more
than three days to ensure a steady state of morphine
and prior to this, all patients had received either oral or
intravenous morphine. Therefore, all patients had used
morphine for some time and were as expected titrated
to different doses of morphine reflecting the known
large interindividual dose variability of morphine given
for cancer pain. Finally, the numbers of patients were
relatively low in this study. However, the total number
of samples was ninety-six due to repeated measure-
ments. One of the study’s strengths was that variability
of pharmacokinetic observation was lower because of
that all patients received morphine intravenously. Fur-
thermore, this study is the first study on morphine
pharmacokinetics during chronic morphine therapy for
cancer pain in ethnic Koreans. Our findings would
Table 5 Linear regression model of factors predictive of serum and urine concentrations of morphine (n = 24)
Outcome Factors Contributing to
outcome
Estimates for individual factors with model 1 Estimate for model 1 Estimate for model 2
Coef. P-value Adjusted R2 Adjusted R2
Serum
M (Day 1) Morphine dose (mg/24 h) 0.60 0.01 0.33 0.08
Urine
M (Day 1) Morphine dose (mg/24 h) 0.52 0.61 0.10 0.14
Age −2.05 0.06
Gender −2.02 0.06
M (Day 2) Morphine dose (mg/24 h) 0.97 0.00 0.40 −0.05
Creatinine −0.44 0.07
Gender −0.48 0.03
M (Day3) Morphine dose (mg/24 h) 0.58 0.01 0.56 0.29
Estimated Model 1: Independent factors in all analyses were morphine dose, gender, daily intravenous fluid amounts, creatinine, ALT, and age
Estimated Model 2: Independent factors in all analyses were gender, daily intravenous fluid amounts, creatinine, ALT, and age (Morphine dose was omitted from
Model 1)
As for Urine model, daily urine output was used instead of daily intravenous fluid amounts in each model
Coef standardized coefficient in regression model, M Morphine concentration (nmol/liter), ALT alanine transaminase
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promote further similar studies using non-invasive
methods such as urine tests, and we also suggest similar
investigations for other opioids (e.g., fentanyl and
oxycodone).
Conclusion
Spot urine concentrations of morphine and its metabo-
lites were highly correlated to those of serum. Urine
tests can be considered if evaluations of morphine/me-
tabolites levels are needed in patients receiving continu-
ous intravenous morphine. Clinical use of routine
monitoring still requires further investigations.
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